The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Medpage Today on MSN3d
FDA OKs New Option for Rare Immune-Mediated VasculitisThe FDA approved the asthma drug benralizumab (Fasenra) as a new therapy for adults with eosinophilic granulomatosis with ...
In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.
AstraZeneca’s Fasenra (benralizumab) met its primary endpoint in the MANDARA trial by demonstrating non-inferiority to the ...
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
Medpage Today on MSN2mon
Benralizumab Led to Histologic Responses in Eosinophilic EsophagitisMore patients with eosinophilic esophagitis experienced a histologic response with benralizumab (Fasenra) compared with ...
AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...
The phase IIIA trials randomized 792 patients ages 12 and older with severe asthma in a 2:1 ratio to depemokimab (100 mg ...
AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...
The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback